Intrinsic4D Announces Retention of Market Maker

BLOOMFIELD HILLS, MICHIGAN--(Marketwired - July 6, 2016) - Intrinsic4D Inc. ("Intrinsic4D") (TSX VENTURE:IFD) is pleased to announce that it has retained Mackie Research Capital Corporation ("Mackie") to provide market making services to the company in compliance with the guidelines of the TSX Venture Exchange (the "TSXV"). Mackie will trade shares of Intrinsic4D on the TSXV for the purposes of maintaining an orderly market and improving the liquidity of Intrinsic4D's shares.

In consideration for their services, Intrinsic4D has agreed to pay Mackie $3,000 per month for a period of 12 months in 3 month increments. The agreement may be terminated at any time by Intrinsic4D or Mackie. There are no performance factors contained in the agreement and Mackie will not receive any shares or options from Intrinsic4D as compensation for the services it will render. Intrinsic4D and Mackie are unrelated and unaffiliated entities, but Mackie has provided investment banking services to Intrinsic4D in the past and Mackie and/or its clients may have an interest, directly or indirectly, in the securities of Intrinsic4D. The agreement is subject to regulatory approval.

About Mackie Research Capital Corporation

Mackie is one of Canada's largest independent full service investment firms, and proudly traces its roots back to 1921. Mackie is privately owned by many of its 300 employees. As a fully integrated national investment dealer, Mackie offers a full complement of capital markets and wealth management services to private clients, institutions and growth companies.

About Intrinsic4D Inc.

Intrinsic4D through its Authentic brand, is the developer of the patented and FDA-cleared transformative software-as-a-service medical platform servicing the medical-legal industry and through its patented and disruptive Stenosis Severity Mapping (SSM) Cardio solution aims to reduce the $13 billion of unnecessary cardiac catheterizations performed annually, attributed to false positive reads of diagnostic tests for evaluating coronary artery disease.

Intrinsic4D website - www.intrinsic4d.com

The information provided in this press release regarding Mackie has been provided by Mackie and has not been independently verified by Intrinsic4D.

Disclaimer for Forward-Looking Information

Certain statements contained in this press release constitute forward-looking information within the meaning of applicable securities laws. Forward-looking information may relate to Intrinsic4D's future outlook and anticipated events or results. Particularly, statements regarding future results, performance, achievements and prospects or opportunities for Intrinsic4D are forward looking statements. Although the forward-looking statements contained in this press release are based upon assumptions that management of Intrinsic4D believes are reasonable based on information currently available to management, there can be no assurance that actual results will be consistent with these forward-looking statements. Forward-looking statements necessarily involve known and unknown risks and uncertainties, many of which are beyond Intrinsic4D's control, which may cause actual results to differ materially from those expressed or implied by such forward-looking statements. The forward- looking statements made in this press release, including the results of the services provided by Mackie, relate only to events or information as of the date hereof. Except as required by applicable law, Intrinsic4D undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.